Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: procedure (650), etiquette (1), practice (609)

Regorafenib

Description: Chemotherapy Protocol Hepatocellular Cancer Regorafenib Regimen • Hepatocellular – Regorafenib Indication • Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Regorafenib.pdf

InP-Cisplatin-Fluorouracil

Description: Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN-FLUOROURACIL In-Patient Regimen Regimen • Head and Neck Cancer – InP-Cisplatin-Fluorouracil Indication • Neoadjuvant
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/InP-Cisplatin-Fluorouracil.pdf

Cisplatin-Fluorouracil

Description: Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN-FLUOROURACIL Regimen • Head and Neck Cancer – Cisplatin-Fluorouracil Indication • Neoadjuvant and palliative treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin-Fluorouracil.pdf

Cisplatin (40)-Radiotherapy

Description: Chemotherapy Protocol HEAD AND NECK CANCER CISPLATIN (40) RT Regimen Head and Neck Cancer – Cisplatin (40) RT Indication Radical treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Cisplatin40-Radiotherapy.pdf

HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-FLUDARABINE-MELPHALAN-METHOTREXATE (GVHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabFludarabineMelphalan-VUD-Methotrexate-GvHD.pdf

Ponatinib

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Ponatinib All licensed indications are not funded therefore an application for funding is required before prescribing
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Ponatinib.pdf

NilotinibAccelerated

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Nilotinib (accelerated phase) Regimen • CML – Nilotinib (accelerated phase) Indication • Nilotinib is an option for the treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/NilotinibAccelerated.pdf

ImatinibChronic

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Regimen IMATINIB (chronic phase) • CML – Imatinib (chronic phase) Indication • As the preferred first-line treatment for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/ImatinibChronic.pdf

ImatinibAccelerated

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia Regimen IMATINIB (accelerated phase) • CML - Imatinib (accelerated phase) Indication • As the preferred option for the treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/ImatinibAccelerated.pdf

Hydroxycarbamide

Description: Chemotherapy Protocol Chronic Myeloid Leukaemia (CML) Hydroxycarbamide Regimen • CML - Hydroxycarbamide Indication • Chronic or accelerated phase chronic myeloid leukaemia in those who
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CML/Hydroxycarbamide.pdf

391 to 400 of 698

Previous … 38 39 40 41 42 … Next